GERN logo

Geron Corporation Stock Price

NasdaqGS:GERN Community·US$816.7m Market Cap
  • 4 Narratives written by author
  • 1 Comments on narratives written by author
  • 37 Fair Values set on narratives written by author
Create a narrative

GERN Share Price Performance

US$1.29
-2.98 (-69.79%)
78.5% undervalued intrinsic discount
US$6.00
Fair Value
US$1.29
-2.98 (-69.79%)
78.5% undervalued intrinsic discount
US$6.00
Fair Value
Price US$1.29
AnalystHighTarget US$6.00
AnalystConsensusTarget US$3.63
WaneInvestmentHouse US$2.42

GERN Community Narratives

AnalystHighTarget·
Fair Value US$6 78.5% undervalued intrinsic discount

Precision Medicine And Telomerase Inhibition Will Expand Therapeutic Markets

1users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AnalystConsensusTarget·
Fair Value US$3.63 64.4% undervalued intrinsic discount

Aging Population Trends Will Expand Hematology Market Opportunity

1users have liked this narrative
0users have commented on this narrative
19users have followed this narrative
WaneInvestmentHouse·
Fair Value US$2.42 46.7% undervalued intrinsic discount

Q1 2025 Earnings Call Highlights: Navigating Revenue Challenges and Strategic amid investor court case

0users have liked this narrative
1users have commented on this narrative
4users have followed this narrative

GERN Community Fair Values

View all narratives

Recent GERN News & Updates

Here's Why Geron (NASDAQ:GERN) Can Manage Its Debt Despite Losing Money

Aug 07
Here's Why Geron (NASDAQ:GERN) Can Manage Its Debt Despite Losing Money

Geron Corporation's (NASDAQ:GERN) Shares Climb 30% But Its Business Is Yet to Catch Up

Jun 13
Geron Corporation's (NASDAQ:GERN) Shares Climb 30% But Its Business Is Yet to Catch Up

Geron Corporation Key Details

US$164.4m

Revenue

US$84.0m

Cost of Revenue

US$80.4m

Gross Profit

US$168.4m

Other Expenses

-US$88.0m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-0.14
Gross Margin
48.90%
Net Profit Margin
-53.52%
Debt/Equity Ratio
45.8%

Geron Corporation Competitors

 
 
 
 
 
 
 
 
 
 
 
 
View more competitors

Snowflake Analysis

Undervalued with high growth potential.

0 Risks
3 Rewards
View Full Analysis

About GERN

Founded
1990
Employees
229
CEO
Harout Semerjian
WebsiteView website
www.geron.com

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.

Market Insight

Header cover image

✨Rare Earths: Tiny Market, Outsized Influence

Richard Bowman avatarRichard Bowman
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Last Week
⚡ Utilities: Defensive Dividends Meet the AI Power Surge

⚡ Utilities: Defensive Dividends Meet the AI Power Surge

U.S. Market Performance

  • 7 Days: 0.4%
  • 3 Months: 7.8%
  • 1 Year: 17.8%
  • Year to Date: 14.7%
In the last week, the market has stayed flat, however the Healthcare sector stood out, gaining 3.7%. As for the longer term, the market has risen 18% in the past 12 months. Looking forward, earnings are forecast to grow by 15% annually. Market details ›